BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22388918)

  • 1. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.
    Pisal DS; Kosloski MP; Middaugh CR; Bankert RB; Balu-Iyer SV
    J Pharm Sci; 2012 Jun; 101(6):2055-65. PubMed ID: 22388918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
    Shi Q; Kuether EL; Schroeder JA; Perry CL; Fahs SA; Cox Gill J; Montgomery RR
    J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
    Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
    Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
    Healey JF; Parker ET; Lollar P
    J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
    Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
    Blood; 2012 Sep; 120(12):2512-20. PubMed ID: 22855607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemophilia A and B mice, but not VWF
    Taves S; Sun J; Livingston EW; Chen X; Amiaud J; Brion R; Hannah WB; Bateman TA; Heymann D; Monahan PE
    Sci Rep; 2019 Oct; 9(1):14428. PubMed ID: 31594977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
    Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
    Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
    Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
    J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
    Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
    Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.